Skip to main content
← Science / Explained

SERIES: MYTHS READ AGAINST THE SCIENCE

Pancreatitis risk is real, and the absolute rate is low

The Label

The Wegovy label lists acute pancreatitis in the Warnings and Precautions section. The reported incidence in clinical studies is low, but not zero.

Acute pancreatitis is a labeled warning for semaglutide and tirzepatide products. It has been reported in both diabetes-treatment and weight-management trial or label contexts, but this source check did not find a stratified analysis proving that risk is independent of diabetes status.

The Symptom

The classic presentation is severe persistent abdominal pain, often radiating to the back, sometimes with nausea and vomiting.

That isn't the routine GI side-effect pattern. It's the symptom that pulls the peptide out of "feels normal" and into "needs evaluation."

What this means

References1 sources

How to read these sources

This article uses primary sources and reviews to separate mechanism, human evidence, and context.

Official LabelRegulator documents
Show 4 more source types
Human TrialStudies in people
ReviewExpert synthesis
MechanismCell and pathway logic
Public UpdateNews or announcements
  1. Official Label

    FDA-approved prescribing information (Wegovy)

    U.S. Food and Drug Administration / Novo Nordisk

    Novo Nordisk · 2026 WEGOVY (semaglutide) prescribing information: 5.2 Acute Pancreatitis Read source

    Used Here For

    Grounding the pancreatitis question in the approved label's acute pancreatitis warning.

    Good For

    The FDA-approved facts on labeled pancreatitis risk.

    Not For

    Diagnosing pancreatitis or giving personal medical advice.

    FDA-approved labeling, DailyMed (National Library of Medicine), updated June 18, 2026